The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Ozanimod (Zeposia) became the third oral S1P modulator approved by the FDA for the treatment of multiple sclerosis,
A new blood test for Alzheimer disease could provide a more sensitive, accurate indicator of plaques and tangles corresponding to the disease in living people.
Risdiplam is the first at-home, orally administered treatment for spinal muscular atrophy in adults and children aged 2 months and older.
Research may address the lack of effective treatments for mental fatigue among patients with multiple sclerosis.
Spinal muscular atrophy is the leading genetic cause of death in infants.
The combination medication is used to treat the symptoms of tension or muscle contraction headaches. The drug is only available via a prescription from a physician.
New molecules could the brain’s immune system to better control epilepsy.
Tofersen proves safe in clinical trials in the treatment of amyotrophic lateral sclerosis.
The study concluded that pharmacists reportedly scored higher on the knowledge test than neurologists and nurse practitioners.
Regardless of the channel through which a specialty medication is billed and filled, management strategies will be an essential cornerstone to controlling costs.
Low back pain is one of the leading reasons people seek medical care and the number 1 cause of disability globally.
The key to better outcomes for patients with MS is to address it early.